Cargando…
Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy
In the last decade, cancer immunotherapy has emerged as an effective alternative to traditional therapies such as chemotherapy and radiation. In contrast to the latter, cancer immunotherapy has the potential to distinguish between cancer and healthy cells, and thus to avoid severe and intolerable si...
Autores principales: | Nabergoj, Sanja, Mlinarič‐Raščan, Irena, Jakopin, Žiga |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767550/ https://www.ncbi.nlm.nih.gov/pubmed/30548868 http://dx.doi.org/10.1002/med.21557 |
Ejemplares similares
-
Nucleotide-Binding Oligomerization Domain 1/Toll-Like Receptor 4 Co-Engagement Promotes Non-Specific Immune Response Against K562 Cancer Cells
por: Guzelj, Samo, et al.
Publicado: (2022) -
Structural Fine-Tuning
of Desmuramylpeptide NOD2 Agonists
Defines Their In Vivo Adjuvant Activity
por: Guzelj, Samo, et al.
Publicado: (2021) -
The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies
por: Markovič, Tijana, et al.
Publicado: (2022) -
Nucleotide-binding oligomerization domain 1 and gastrointestinal disorders
por: WATANABE, Tomohiro, et al.
Publicado: (2017) -
Multifaceted roles and regulation of nucleotide-binding oligomerization domain containing proteins
por: Dixon, Charneal L., et al.
Publicado: (2023)